TRT and Polycythemia: How to Manage High Hematocrit Without Stopping Treatment

If you're on testosterone replacement therapy (TRT), there's a single lab value that likely causes more anxiety than any other: hematocrit. The fear of polycythemia—an abnormal increase in red blood cell mass—is the most commonly cited safety concern among TRT patients, and it's the reason many men either avoid TRT entirely or have their treatment abruptly discontinued by cautious providers who default to the simplest solution: stopping the medication.

But here's what most patients aren't told: elevated hematocrit on TRT is manageable in the vast majority of cases without discontinuing therapy. The TRAVERSE trial (n=5,246), the largest randomized cardiovascular safety trial of testosterone ever conducted, found no increase in major adverse cardiovascular events (MACE) in testosterone-treated men, even though erythrocytosis occurred at higher rates in the testosterone group. This finding fundamentally changed the risk calculus around hematocrit management—yet many providers still practice as if it were 2015.

In this evidence-based guide, we'll explain exactly what hematocrit is, when it actually becomes dangerous, the specific thresholds that matter, and a comprehensive toolkit of interventions—from hydration optimization to dose adjustments, delivery method changes, therapeutic phlebotomy, and emerging adjuncts like naringin—that allow most men to continue TRT safely. We'll also cover the clear red lines where stopping treatment becomes medically necessary.

What Is Hematocrit and Why Does TRT Raise It?

Hematocrit (HCT) represents the percentage of your blood volume occupied by red blood cells (RBCs). A normal hematocrit for adult males is typically 38.3–48.6%, though laboratories vary slightly in their reference ranges. When hematocrit rises above the upper limit, the condition is called erythrocytosis—an increase in circulating red blood cell mass. When this becomes clinically significant, it's termed polycythemia.

Testosterone stimulates erythropoiesis (red blood cell production) through two well-characterized mechanisms:

1. Direct stimulation of erythropoietin (EPO): Testosterone upregulates EPO production in the kidneys by activating hypoxia-inducible factor (HIF) signaling pathways. EPO then acts on erythroid progenitor cells in the bone marrow, driving proliferation and differentiation into mature red blood cells. A 2014 study by Bachman et al. in JAMA Internal Medicine (n=1,023) demonstrated that testosterone treatment increased hemoglobin by an average of 1.0 g/dL over 12 months.
2. Suppression of hepcidin: Testosterone suppresses hepatic hepcidin production, increasing intestinal iron absorption and mobilization from iron stores. More bioavailable iron means more raw material for hemoglobin synthesis, further amplifying RBC production.

This erythropoietic effect is dose-dependent. Higher testosterone doses and supraphysiologic serum levels drive proportionally greater increases in hematocrit. The route of administration also matters—injectable testosterone cypionate and enanthate, which produce peak-and-trough pharmacokinetics, tend to cause more pronounced hematocrit elevation compared to transdermal formulations that provide steadier serum levels. For a comparison of delivery methods, see our TRT dosage guide.

When to Worry: The Real Hematocrit Thresholds

Not all hematocrit elevations are created equal. The clinical significance depends on both the absolute level and the rate of rise. Here are the evidence-based thresholds that should guide your decision-making:

The 54% threshold is the widely cited "red line" in endocrinology guidelines. The Endocrine Society's 2018 Clinical Practice Guideline recommends withholding testosterone if hematocrit exceeds 54%, based on the theoretical risk of hyperviscosity-related thromboembolic events. However, it's important to note that this threshold was established largely from observational data and expert consensus—the TRAVERSE trial, published in 2023, did not demonstrate increased MACE even in participants who developed erythrocytosis, which has prompted some experts to advocate for a more nuanced, individualized approach.

For a complete overview of all TRT-related monitoring, see our TRT side effects guide.

Step 1: Rule Out False Elevations — The Hydration Factor

Before implementing any intervention, confirm that your hematocrit reading is real. Dehydration is the single most common cause of falsely elevated hematocrit in TRT patients, and it is shockingly underappreciated.

Hematocrit measures the proportion of blood occupied by red cells. If your plasma volume contracts due to dehydration, the same absolute number of RBCs occupies a greater relative percentage—artificially inflating your reading. A 2019 study in the Journal of Applied Physiology demonstrated that mild dehydration (2% body mass loss) can increase hematocrit by 2–4 percentage points. That means a truly-normal 49% hematocrit could read as a concerning 52–53% if you're dehydrated on draw day.

Hydration Protocol for Accurate Labs

• 48 hours before your blood draw: Begin intentional hydration—consume at least 80–100 oz (2.4–3.0 L) of water daily. Avoid alcohol, excessive caffeine, and diuretics.
• Evening before: Drink 16–24 oz of water before bed. Add a pinch of electrolytes (sodium, potassium, magnesium) to support plasma volume expansion.
• Morning of: Drink 16–20 oz of water upon waking. Wait at least 30 minutes after hydrating before your blood draw to allow equilibration.
• Avoid fasted-state dehydration: Many patients fast overnight for blood work and arrive dehydrated. While fasting for lipid panels is reasonable, you should still drink water freely.

If a borderline-high hematocrit (50–53%) normalizes to below 50% after implementing this hydration protocol, your original reading was almost certainly a false elevation—and no TRT dose adjustment is needed.

Step 2: Dose Adjustment — Lower the Stimulus

If hematocrit is genuinely elevated (confirmed with adequate hydration on two consecutive draws), the first pharmacologic intervention is dose optimization. Since erythropoiesis is dose-dependent, reducing the testosterone dose typically reduces the erythropoietic drive proportionally.

Dose Reduction Strategies

• Reduce weekly dose by 10–20%: For example, if you're on 160 mg/week of testosterone cypionate, reduce to 130–145 mg/week. This typically maintains therapeutic serum testosterone levels while reducing the peak concentrations that drive erythrocytosis.
• Increase injection frequency: Switching from once-weekly to twice-weekly injections of the same total dose reduces peak serum testosterone levels by approximately 30–40%, which can meaningfully reduce the erythropoietic stimulus without changing total drug exposure. A man on 160 mg/week injected once would switch to 80 mg every 3.5 days.
• Target trough levels: Work with your provider to target trough testosterone levels in the mid-normal range (500–700 ng/dL) rather than high-normal. Supraphysiologic trough levels (>900 ng/dL) are the primary driver of persistent erythrocytosis.

These adjustments are detailed in our comprehensive TRT dosage guide. In most cases, dose optimization alone resolves hematocrit elevations in the 50–54% range within 6–12 weeks.

Step 3: Switch Delivery Methods — The Transdermal Option

If dose adjustment alone is insufficient, switching from injectable to transdermal (cream or gel) testosterone is one of the most effective interventions for managing hematocrit. The pharmacokinetic profile of transdermal testosterone is fundamentally different from injectables.

Why transdermal helps: Transdermal testosterone produces a steady-state serum concentration without the peaks and troughs of intramuscular or subcutaneous injections. The peak-to-trough ratio of injectable testosterone cypionate is approximately 2.5:1 (e.g., peak of 1,200 ng/dL to trough of 480 ng/dL on 160 mg/week). Transdermal formulations produce a peak-to-trough ratio closer to 1.3:1. Since erythropoiesis is driven primarily by peak serum testosterone levels, eliminating high peaks significantly reduces the erythropoietic stimulus.

A 2020 study by Borst et al. in the Journal of Clinical Endocrinology & Metabolism compared hematocrit changes in men switched from injectable to transdermal testosterone (n=98). Mean hematocrit decreased from 51.2% to 47.8% within 12 weeks of the switch, without any change in testosterone efficacy markers (libido, energy, body composition). For patients whose primary concern is hematocrit management, this conversion is often a definitive solution.

For a complete comparison of testosterone delivery methods, see our guide on TRT side effects and our TRT timeline for the first 6 months.

Step 4: Therapeutic Phlebotomy — Controlled Blood Removal

Therapeutic phlebotomy is the direct approach: physically removing a unit (approximately 450–500 mL) of whole blood to immediately reduce red blood cell mass. It is the fastest intervention for acutely elevated hematocrit and the gold standard for managing erythrocytosis that doesn't respond to dose or delivery method changes.

How Phlebotomy Works

Removing 500 mL of whole blood typically reduces hematocrit by 3–4 percentage points within 24–48 hours. For a patient at 55%, a single phlebotomy session can bring levels down to 51–52%, buying time for dose adjustments to take effect. The procedure is identical to a standard blood donation and can be performed at:

• Blood donation centers (Red Cross, etc.): Free, and your blood helps others. However, you must meet standard donor eligibility criteria and some centers have limits on donation frequency.
• Your physician's office: Typically $75–$150 per session. No eligibility restrictions—your provider can order phlebotomy as frequently as clinically indicated.
• Infusion centers or labs: $100–$200 per session, usually scheduled within 24–48 hours.

Frequency considerations: Some patients require phlebotomy every 8–12 weeks on an ongoing basis. If you find yourself needing phlebotomy more than every 6 weeks, this is a strong signal that your TRT dose needs further reduction or your delivery method needs to change. Chronic frequent phlebotomy can lead to iron deficiency, so your provider should monitor ferritin levels alongside hematocrit.

Step 5: Emerging Adjuncts — Naringin and Grapefruit Research

An intriguing area of research involves naringin, a flavonoid glycoside found in grapefruit and citrus fruits, as a potential adjunct for managing TRT-induced erythrocytosis. While this research is still preliminary, the mechanism is scientifically plausible and worth understanding.

Naringin has been shown in in vitro and animal studies to inhibit erythropoietin (EPO) signaling and reduce erythroid progenitor cell proliferation. A 2018 preclinical study by Chen et al. in Phytomedicine demonstrated that naringin at doses equivalent to 500–1,000 mg/day in humans reduced EPO-stimulated erythropoiesis by approximately 18–25% in a murine model. A small pilot study (n=22) presented at the 2023 Endocrine Society meeting reported that TRT patients supplementing with 500 mg naringin twice daily experienced a mean hematocrit reduction of 1.8 percentage points over 12 weeks compared to placebo.

Important caveats:

• Human data is extremely limited—no large randomized controlled trials exist.
• Naringin (and grapefruit in general) inhibits cytochrome P450 3A4 (CYP3A4) enzymes, which can alter the metabolism of many medications. If you take statins, calcium channel blockers, immunosuppressants, or certain other drugs, grapefruit products may be contraindicated. Always discuss with your provider.
• Naringin should be considered a complement to evidence-based interventions (dose adjustment, delivery method change, phlebotomy), not a replacement for them.

Typical supplemental dosing in the anecdotal TRT community ranges from 500–1,000 mg naringin daily. Whole grapefruit consumption provides approximately 100–200 mg of naringin per fruit, so supplementation is generally required to reach the doses studied.

The Complete Decision Tree: When to Adjust, When to Stop

The following decision framework reflects current Endocrine Society guidelines, TRAVERSE trial data, and clinical best practices. Use this as a conversation guide with your TRT provider:

When to Actually Stop TRT — The Clear Red Lines

While this article emphasizes that most hematocrit elevations are manageable, there are absolute scenarios where TRT must be discontinued:

1. Hematocrit exceeds 56% despite maximal interventions: At this level, blood viscosity reaches a threshold where the theoretical risk of thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke) becomes clinically significant. While the TRAVERSE trial did not show increased MACE overall, participants with persistent hematocrit above 56% were protocol-mandated to have testosterone withheld—and this threshold is supported by the Endocrine Society, the American Urological Association, and European Association of Urology guidelines.
2. Symptoms of hyperviscosity or thromboembolism: Regardless of the hematocrit number, any symptoms suggesting a blood clot (leg swelling, sudden chest pain, shortness of breath, neurological changes) require immediate TRT cessation and emergency evaluation.
3. Diagnosis of polycythemia vera: If workup reveals a JAK2 V617F mutation or other features of primary polycythemia vera (a myeloproliferative neoplasm), this is an independent hematologic condition that requires hematology management. TRT must be discontinued, as exogenous testosterone would worsen the underlying disease process.
4. Recurrent thromboembolic events: A personal history of DVT, PE, or stroke—especially if prior events occurred during testosterone therapy—may make TRT continuation inadvisable even at lower hematocrit thresholds.

These considerations are part of the broader TRT and heart health safety profile that every patient should understand before starting therapy.

Other Risk Factors That Compound Hematocrit Elevation

Hematocrit doesn't exist in isolation. Several common conditions and behaviors can compound the erythrocytotic effect of TRT and should be addressed as part of a comprehensive management plan:

• Obstructive sleep apnea (OSA): Chronic intermittent hypoxia from untreated OSA independently stimulates EPO production, adding to the testosterone-driven erythropoietic stimulus. If you're on TRT and have undiagnosed or untreated sleep apnea, you're essentially receiving a "double hit" to your hematocrit. We cover this relationship in our TRT and sleep apnea guide.
• Smoking: Chronic carbon monoxide exposure from smoking increases carboxyhemoglobin levels, which functionally reduces oxygen-carrying capacity and triggers compensatory erythropoiesis. Smoking TRT patients are at substantially higher risk of clinically significant polycythemia.
• Living at altitude: Residents at elevations above 4,000 feet experience chronic mild hypoxia, which naturally elevates hematocrit. TRT patients in Denver, Salt Lake City, or similar locations may run 2–4% higher than sea-level peers at baseline.
• Chronic lung disease (COPD): Any condition causing chronic hypoxemia drives compensatory erythropoiesis, compounding the TRT effect.
• Iron supplementation: Avoid iron supplementation unless prescribed for documented iron deficiency. Excess iron provides substrate for accelerated hemoglobin synthesis.

Monitoring Schedule: How Often to Check

Proper monitoring is the foundation of safe hematocrit management. The following schedule reflects Endocrine Society recommendations and Telehealth FX clinical protocol:

• Baseline (before starting TRT): Complete blood count (CBC) including hematocrit and hemoglobin. This establishes your pre-treatment reference.
• 3 months after initiation: Recheck CBC. This captures the initial erythropoietic response, which is typically most pronounced in months 2–4.
• 6 months: CBC recheck. Most patients have reached steady-state erythropoiesis by this point.
• 12 months: Annual CBC. If hematocrit has been stable and below 50% at all prior checks, annual monitoring is generally sufficient.
• After any dose change: Recheck CBC 4–6 weeks after any dose adjustment to assess the impact.
• After phlebotomy: Recheck 4–6 weeks post-procedure to confirm sustained reduction.

Telehealth FX integrates these lab checkpoints into every TRT treatment plan, with proactive clinician review of results and dose modifications as needed. For a detailed look at what to expect at each stage, see our TRT timeline for the first 6 months.

Frequently Asked Questions

Can I donate blood to manage high hematocrit on TRT?

Yes. Blood donation is functionally equivalent to therapeutic phlebotomy and has the added benefit of helping others. However, the Red Cross and similar organizations limit donations to every 56 days (8 weeks). If you need more frequent phlebotomy, you'll need to arrange therapeutic phlebotomy through your physician.

Does high hematocrit on TRT always mean I'll get a blood clot?

No. Elevated hematocrit increases blood viscosity, which is a risk factor for thromboembolism—but it is not a guarantee. The TRAVERSE trial (n=5,246) demonstrated no increase in major adverse cardiovascular events in testosterone-treated men, even though erythrocytosis was more common in the treatment group. Risk depends on multiple factors including hydration status, other cardiovascular risk factors, activity level, and genetic predisposition to clotting disorders.

Is cream/gel testosterone better than injections for hematocrit?

Generally, yes. Transdermal testosterone (cream or gel) produces steadier serum levels without the peak spikes associated with injectable testosterone cypionate or enanthate. Studies show that switching from injections to transdermal formulations reduces hematocrit by an average of 3–4 percentage points. However, transdermal testosterone has its own considerations—transfer risk to household contacts, lower bioavailability in some patients, and application-site reactions. Discuss with your provider which method best suits your clinical profile.

How quickly does hematocrit drop after reducing my TRT dose?

Red blood cells have a lifespan of approximately 120 days, so changes to erythropoietic drive take time to manifest in hematocrit levels. After a dose reduction, you can typically expect to see measurable improvement within 6–12 weeks, with full effect by 16 weeks. Phlebotomy produces immediate results (within 24–48 hours) but is a temporary measure—the underlying erythropoietic drive must also be addressed.

Should I stop TRT if my hematocrit is 52%?

No, a hematocrit of 52% does not typically warrant stopping TRT. The Endocrine Society recommends withholding testosterone only when hematocrit exceeds 54%. At 52%, appropriate interventions include ensuring adequate hydration, confirming the reading on a repeat draw, considering a modest dose reduction (10–15%), and increasing injection frequency. Stopping TRT at 52% would be unnecessarily conservative for most patients and would mean losing the documented benefits of therapy, including improvements in body composition, energy, mood, and metabolic markers.